406 related articles for article (PubMed ID: 22349515)
21. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
22. Vaccine therapy for melanoma: current status and future directions.
Terando AM; Faries MB; Morton DL
Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
[TBL] [Abstract][Full Text] [Related]
23. Advances in specific immunotherapy of malignant melanoma.
Curiel-Lewandrowski C; Demierre MF
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):167-85; quiz 186-8. PubMed ID: 10906637
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
25. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
Di Mitri D; Toso A; Alimonti A
Clin Cancer Res; 2015 Jul; 21(14):3108-12. PubMed ID: 25967145
[TBL] [Abstract][Full Text] [Related]
26. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
Jiang H; Gebhardt C; Umansky L; Beckhove P; Schulze TJ; Utikal J; Umansky V
Int J Cancer; 2015 May; 136(10):2352-60. PubMed ID: 25353097
[TBL] [Abstract][Full Text] [Related]
27. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
29. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V; Sevko A
Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2359s-2365s. PubMed ID: 16609059
[TBL] [Abstract][Full Text] [Related]
31. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
32. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
Talmadge JE
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
[TBL] [Abstract][Full Text] [Related]
33. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
[TBL] [Abstract][Full Text] [Related]
35. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells.
Younos I; Donkor M; Hoke T; Dafferner A; Samson H; Westphal S; Talmadge J
Int Immunopharmacol; 2011 Jul; 11(7):816-26. PubMed ID: 21376153
[TBL] [Abstract][Full Text] [Related]
36. [Role of chemokines in melanoma progression].
Monteagudo C; Pellín-Carcelén A; Martín JM; Ramos D
Actas Dermosifiliogr; 2011 Sep; 102(7):498-504. PubMed ID: 21531362
[TBL] [Abstract][Full Text] [Related]
37. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
39. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
40. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]